[go: up one dir, main page]

BRPI0606606A2 - composições estáveis contendo prostaglandina - Google Patents

composições estáveis contendo prostaglandina

Info

Publication number
BRPI0606606A2
BRPI0606606A2 BRPI0606606-2A BRPI0606606A BRPI0606606A2 BR PI0606606 A2 BRPI0606606 A2 BR PI0606606A2 BR PI0606606 A BRPI0606606 A BR PI0606606A BR PI0606606 A2 BRPI0606606 A2 BR PI0606606A2
Authority
BR
Brazil
Prior art keywords
prostaglandin
containing compositions
acid ester
chemical stability
alkanoic acid
Prior art date
Application number
BRPI0606606-2A
Other languages
English (en)
Inventor
Victor Deaciuc
Michael Hagan
Hashem Heiati
Karem Kostick Jette
Gregory C Visor
Ian G C Mcaffer
Peter Tasko
Original Assignee
Breath Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Ltd filed Critical Breath Ltd
Publication of BRPI0606606A2 publication Critical patent/BRPI0606606A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

COMPOSIçõES ESTáVEIS CONTENDO PROSTAGLANDINA. A presente invenção se refere à composição farmacêutica contendo uma prostaglandina e um éster de ácido alcanóico de um sorbitol polietoxilado em uma quantidade eficaz para intensificar a estabilidade química da prostaglandina e o uso da mesma para o tratamento de condições oftálmicas. Também divulgados são métodos para intensificação da estabilidade química de uma composição contendo prostaglandina através de uso de um éster de ácido alcanóico de um sorbitol polietoxilado.
BRPI0606606-2A 2005-01-20 2006-01-18 composições estáveis contendo prostaglandina BRPI0606606A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0501192.9A GB0501192D0 (en) 2005-01-20 2005-01-20 Stable prostaglandin-containing compositions
PCT/US2006/001626 WO2006078659A2 (en) 2005-01-20 2006-01-18 Stable prostaglandin-containing compositions

Publications (1)

Publication Number Publication Date
BRPI0606606A2 true BRPI0606606A2 (pt) 2009-07-07

Family

ID=34259405

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0606606-2A BRPI0606606A2 (pt) 2005-01-20 2006-01-18 composições estáveis contendo prostaglandina

Country Status (16)

Country Link
US (2) US8084501B2 (pt)
EP (1) EP1843744A2 (pt)
JP (2) JP2008528490A (pt)
KR (1) KR20070094793A (pt)
CN (1) CN101106973A (pt)
AU (1) AU2006206649B2 (pt)
BR (1) BRPI0606606A2 (pt)
CA (1) CA2595237A1 (pt)
CZ (1) CZ2007555A3 (pt)
GB (1) GB0501192D0 (pt)
IL (1) IL184111A0 (pt)
IS (1) IS8665A (pt)
NO (1) NO20073699L (pt)
NZ (1) NZ556117A (pt)
WO (1) WO2006078659A2 (pt)
ZA (1) ZA200705428B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI394564B (zh) * 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
US9394520B2 (en) 2006-12-08 2016-07-19 University Of Rochester Expansion of hematopoietic stem cells
JP5297815B2 (ja) * 2007-01-26 2013-09-25 株式会社ポーラファルマ 医薬組成物
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
JP2008247828A (ja) * 2007-03-30 2008-10-16 Wakamoto Pharmaceut Co Ltd ラタノプロストを含有する水性医薬組成物。
CA2853152C (en) * 2007-11-30 2017-04-18 Toltec Pharmaceuticals, Llc Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
US20110136898A1 (en) * 2008-08-05 2011-06-09 University College Cork, National University Of Ireland, Cork Treatment of retinal degeneration
US20100087540A1 (en) * 2008-10-07 2010-04-08 R-Tech Ueno, Ltd. Pharmaceutical composition
WO2011027778A1 (ja) * 2009-09-01 2011-03-10 株式会社アールテック・ウエノ 高眼圧症および緑内障処置のための眼局所投与用組成物
AU2010314863A1 (en) * 2009-11-09 2012-06-14 Allergan, Inc. Compositions for enhancing hair growth
TWI478730B (zh) * 2009-12-03 2015-04-01 Alcon Res Ltd 眼科乳劑
CA2830896A1 (en) * 2011-04-12 2012-10-18 Yukihiko Mashima Aqueous ophthalmic composition
DE102011108948A1 (de) * 2011-07-29 2013-01-31 Achim Göpferich Wässrige, kolloidale Lösungen von lipophilen Substanzen,insbesondere Arzneistofflösungen
CN104208015A (zh) * 2013-05-29 2014-12-17 天津金耀集团有限公司 含有曲伏前列腺素和防腐剂的眼部制剂
PL3103439T3 (pl) * 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
JP6931493B2 (ja) * 2017-06-22 2021-09-08 ヨンスン ファイン ケミカル カンパニー，リミテッド 緑内障治療用点眼組成物
EP4331600A4 (en) * 2021-04-30 2025-04-16 Innovent Biologics (Suzhou) Co., Ltd. OXM3 STORAGE AGENT, OXM3 PREPARATION AND PREPARATION METHOD

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1366215A (en) 1916-08-05 1921-01-18 Vaporackumulator Ab Supplementary power plant for electric centrals
US5165918A (en) * 1988-06-28 1992-11-24 Ciba-Geigy Corporation Antimicrobial ophthalmic solutions containing dodecyl-dimethyl-(2 phenoxyethyl)-ammonium bromide and methods of using the same
DK0458588T3 (da) * 1990-05-22 1995-03-13 R Tech Ueno Ltd Behandling af okulær hypertension med en synergistisk kombination til okulær administration
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
US5972991A (en) 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
US5545665A (en) 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1997023225A1 (en) * 1995-12-22 1997-07-03 Alcon Laboratories, Inc. Combinations of dp and fp type prostaglandins for lowering iop
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
SE9702681D0 (sv) 1997-07-10 1997-07-10 Pharmacia & Upjohn Ab Method and composition for treatment of impotence
SE9702706D0 (sv) 1997-07-11 1997-07-11 Pharmacia & Upjohn Ab Prostaglandin derivatives devoid of side-effects for the treatment of glaucoma
WO1999012899A1 (en) 1997-09-09 1999-03-18 The Procter & Gamble Company A process for making prostaglandin f analogs
US6646001B2 (en) * 1997-12-19 2003-11-11 Alcon Manufacturing, Ltd. Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
US6388128B1 (en) 1998-10-05 2002-05-14 Alcon Manufacturing, Ltd. Stannane synthesis of prostanoids
US6417228B1 (en) * 1998-11-02 2002-07-09 Alcon Manufacturing, Ltd.. 13-Aza prostaglandins for the treatment of glaucoma and ocular hypertension
SE9900025D0 (sv) 1999-01-08 1999-01-08 Synphora Ab Method and composition for treatment of female sexual dysfunction
US6136846A (en) 1999-10-25 2000-10-24 Supergen, Inc. Formulation for paclitaxel
JP3876355B2 (ja) * 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
CN1243548C (zh) 2000-09-13 2006-03-01 参天制药株式会社 滴眼液
US20030018079A1 (en) * 2000-11-13 2003-01-23 Richardson Helene Treatment
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
US7351404B2 (en) * 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
NO317079B1 (no) * 2002-08-02 2004-08-02 Maritime Hydraulics As Stigerorstrekkanordning
US6864282B2 (en) * 2002-08-05 2005-03-08 Allergan, Inc. 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma
US20040076678A1 (en) 2002-08-21 2004-04-22 Sucampo Ag Opthalmic solution
KR20050057251A (ko) 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
EP1843744A2 (en) 2007-10-17
CA2595237A1 (en) 2006-07-27
IS8665A (is) 2007-08-02
ZA200705428B (en) 2008-09-25
NZ556117A (en) 2009-10-30
KR20070094793A (ko) 2007-09-21
GB0501192D0 (en) 2005-03-02
CN101106973A (zh) 2008-01-16
WO2006078659A2 (en) 2006-07-27
US20060270735A1 (en) 2006-11-30
JP2013056948A (ja) 2013-03-28
CZ2007555A3 (cs) 2007-10-10
IL184111A0 (en) 2007-10-31
WO2006078659A3 (en) 2006-11-16
NO20073699L (no) 2007-10-19
WO2006078659A8 (en) 2007-08-30
US8084501B2 (en) 2011-12-27
JP2008528490A (ja) 2008-07-31
AU2006206649B2 (en) 2010-05-27
AU2006206649A1 (en) 2006-07-27
US20120065258A1 (en) 2012-03-15

Similar Documents

Publication Publication Date Title
BRPI0606606A2 (pt) composições estáveis contendo prostaglandina
EA200870216A1 (ru) Амидо соединения и их применение в качестве лекарственных средств
BRPI0507198A (pt) derivados de bisariluréia
NI201000022A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparación, su aplicación como medicamentos, composiciones farmacéuticas y nueva utilización principalmente como inhibidores de met.
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
SV2011003903A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
BR112015000578A2 (pt) moduladores da via do complemento e usos dos mesmos
BRPI0609121B8 (pt) 1h-benzimidazol-4-carboxamidas substituídas com um carbono quaternário na posição 2
ECSP10010167A (es) Composiciones oftálmicas novedosas
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
BR112012021771A2 (pt) métodos de uso de inibidores de contransportadores de sódio-glicose 1 e 2.
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
UY31046A1 (es) Derivados sustituidos de n-(3,4-dihidro-2h-cromen-3-il)formamida y n-(1, 2,3 ,4-tetrahidronaftalen-2-il)formamida, sales de los mismos, composiciones que los contienen, procedimientos para su preparacion y aplicaciones
BR112015010908A2 (pt) derivado de pirrol sulfonamida, método de preparação para o mesmo e aplicação médica do mesmo
CR10479A (es) Modulares bencimidazolicos de vr1
PA8783401A1 (es) Derivados de piperidina/piperazina
EA200700096A1 (ru) Производные 2-карбамид-4-фенилтиазола, способ их получения и их применение в терапии
BRPI0806789B8 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BRPI0514766A (pt) composições farmacêuticas
BR112018069712A2 (pt) composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a.
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
BR112013026361A2 (pt) derivados de glicosídeo e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 9A E 10A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.